FDA meeting, page-14

colin and aristarchus, sadly I believe you are wrong.
There are numerous examples of medicines that have been used for decades that don't work (for a specific indication) that , yet still sell well, or are widely prescribed and thus successful products. This applies to OTC as well as prescribed meds.

Women use very expensive hand and face creams with zero evidence of efficacy but there are multinationals that depend on those sales for their profitability. Men chose cars with similar claims of superiority (Mercedes, for example) that are clearly inferior in many objective tests of efficacy or reliability. Much of this effect is due to effective marketing and brand positioning.

Medicines occupy a different but similar place in the market, in that the consumer is often desperate for a cure, clouding objectivity further.

The trials need to "prove" to the statisticians at the FDA, that viva gel works for the specific indication that is is being marketed for. The statisticians from Vivagel will be twisting the data as much as they can to prove their point. The FDA may be doing the opposite or being unbiased, we don't don't know.

Stockrock is entirely correct when he states that the entry timing for people considering buying Starpharma is absolutely not now.
If they request a new trial to will bomb, for at least a number of months or perhaps years util RoW sales kick in. If the FDA give it a green light the share price will certainly jump but will likely reflect the the new value of a starpharma with a decreased risk profile and increased expected earnings in the near to medium term. ie there is little to convince an investor to chose a maybe price int he middle

What we should all be asking ourselves is whether we should continue to hold. Someone clever once said a hold is the same is choosing to buy at this price every day you are not selling.

I have offloaded 50% of my not inconsiderable SPL holding. not at a particularly attractive price. Logic should guide me to do the same with the rest and re-buy when the risk reward ratio has been clarified, anchoring is staying my hand, insight hasn't made me any wiser.

I have owned SPL for in excess of 10 years and have been a strong supporter, as I remain to this day. But the valuation is a different subject